S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
NASDAQ:CELU

Celularity Stock Forecast, Price & News

$6.82
+0.20 (+3.02 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.59
$7.35
50-Day Range
$6.05
$8.70
52-Week Range
$6.00
$13.40
Volume121,749 shs
Average Volume571,536 shs
Market Capitalization$842.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.29
30 days | 90 days | 365 days | Advanced Chart
Receive CELU News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.


Celularity logo

About Celularity

GX Acquisition Corp. entered into a definitive agreement for a business combination with Celularity Inc., which is expected to occur in the second quarter of 2021.

Headlines

Celularity (NASDAQ:CELU) Shares Gap Up to $6.62
October 26, 2021 |  americanbankingnews.com
Celularity (NASDAQ:CELU) Stock Price Down 3.8%
October 25, 2021 |  americanbankingnews.com
Celularity (NASDAQ:CELU) Shares Gap Down to $7.46
October 20, 2021 |  americanbankingnews.com
Celularity (NASDAQ:CELU) Now Covered by Truist Securities
October 19, 2021 |  americanbankingnews.com
Truist Begins Coverage on Celularity (NASDAQ:CELU)
October 19, 2021 |  americanbankingnews.com
Celularity Hires Andrew Pecora as President
September 16, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CELU
Web
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.14 per share

Profitability

Net Income
$-49.26 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$842.02 million
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

763rd out of 1,363 stocks

Pharmaceutical Preparations Industry

371st out of 667 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Celularity (NASDAQ:CELU) Frequently Asked Questions

Is Celularity a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celularity in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celularity stock.
View analyst ratings for Celularity
or view top-rated stocks.

What stocks does MarketBeat like better than Celularity?

Wall Street analysts have given Celularity a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celularity wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Celularity?

Celularity saw a decline in short interest in September. As of September 30th, there was short interest totaling 936,900 shares, a decline of 20.6% from the September 15th total of 1,180,000 shares. Based on an average daily trading volume, of 537,400 shares, the short-interest ratio is presently 1.7 days. Approximately 3.6% of the shares of the company are short sold.
View Celularity's Short Interest
.

When is Celularity's next earnings date?

Celularity is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Celularity
.

How were Celularity's earnings last quarter?

Celularity Inc (NASDAQ:CELU) announced its quarterly earnings results on Sunday, August, 15th. The company reported ($2.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $2.53. The business earned $3.20 million during the quarter.
View Celularity's earnings history
.

What price target have analysts set for CELU?

3 Wall Street analysts have issued 12-month price objectives for Celularity's stock. Their forecasts range from $12.00 to $12.00. On average, they expect Celularity's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 76.0% from the stock's current price.
View analysts' price targets for Celularity
or view top-rated stocks among Wall Street analysts.

What is Celularity's stock symbol?

Celularity trades on the NASDAQ under the ticker symbol "CELU."

How do I buy shares of Celularity?

Shares of CELU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celularity's stock price today?

One share of CELU stock can currently be purchased for approximately $6.82.

How much money does Celularity make?

Celularity has a market capitalization of $842.02 million.

Where are Celularity's headquarters?

How can I contact Celularity?

Celularity's mailing address is 1325 AVENUE OF THE AMERICAS 25TH FLOOR, NEW YORK NY, 10019. The company can be reached via phone at 609-235-1010.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.